Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Prevalence of atopy and staphylococcal superantigen-specific immunoglobulin E (IgE) antibodies and total serum IgE in primary cutaneous T- and B-cell lymphoma.

Vonderheid EC, Hamilton RG, Kadin ME.

J Dermatol. 2019 Dec;46(12):1170-1178. doi: 10.1111/1346-8138.15059. Epub 2019 Oct 6.

PMID:
31587349
2.

A histo-immunopathologic and prognostic study of erythrodermic cutaneous T-cell lymphoma.

Vonderheid EC, Kantor GR, Telang GH, Bujanouskas P, Kadin ME.

J Cutan Pathol. 2019 Dec;46(12):913-924. doi: 10.1111/cup.13564. Epub 2019 Sep 4.

PMID:
31403211
3.

Prognostic Significance of Serum Copper in Patients With Cutaneous T-cell Lymphoma.

Vonderheid EC, Martinez AR.

Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):228-238.e4. doi: 10.1016/j.clml.2018.12.020. Epub 2019 Jan 2.

PMID:
30745139
4.

Pityriasis lichenoides: Long-term follow-up study.

Zang JB, Coates SJ, Huang J, Vonderheid EC, Cohen BA.

Pediatr Dermatol. 2018 Mar;35(2):213-219. doi: 10.1111/pde.13396. Epub 2018 Jan 9.

PMID:
29315771
5.

CD4+CD26- lymphocytes are useful to assess blood involvement and define B ratings in cutaneous T cell lymphoma.

Vonderheid EC, Hou JS.

Leuk Lymphoma. 2018 Feb;59(2):330-339. doi: 10.1080/10428194.2017.1334123. Epub 2017 Jun 9.

PMID:
28595473
6.

Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome.

Walker S, Wang C, Walradt T, Hong BS, Tanner JR, Levinsohn JL, Goh G, Subtil A, Lessin SR, Heymann WR, Vonderheid EC, King BA, Lifton RP, Choi J.

Blood. 2016 Feb 18;127(7):948-51. doi: 10.1182/blood-2015-06-654277. Epub 2015 Dec 23. No abstract available.

7.

Commentary about papular mycosis fungoides, lymphomatoid papulosis and lymphomatoid pityriasis lichenoides: more similarities than differences.

Vonderheid EC, Kadin ME, Telang GH.

J Cutan Pathol. 2016 Apr;43(4):303-12. doi: 10.1111/cup.12653. Epub 2015 Dec 22. Review. No abstract available.

PMID:
26566599
8.

Genomic landscape of cutaneous T cell lymphoma.

Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP.

Nat Genet. 2015 Sep;47(9):1011-9. doi: 10.1038/ng.3356. Epub 2015 Jul 20.

9.

Early changes in miRNA expression are predictive of response to extracorporeal photopheresis in cutaneous T-cell lymphoma.

McGirt LY, Baerenwald DA, Vonderheid EC, Eischen CM.

J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2269-71. doi: 10.1111/jdv.12571. Epub 2014 Jun 9. No abstract available.

10.

Genetic markers associated with progression in early mycosis fungoides.

Johnson VE, Vonderheid EC, Hess AD, Eischen CM, McGirt LY.

J Eur Acad Dermatol Venereol. 2014 Nov;28(11):1431-5. doi: 10.1111/jdv.12299. Epub 2013 Oct 31.

11.

Prognostic factors and risk stratification in early mycosis fungoides.

Vonderheid EC, Pavlov I, Delgado JC, Martins TB, Telang GH, Hess AD, Kadin ME.

Leuk Lymphoma. 2014 Jan;55(1):44-50. doi: 10.3109/10428194.2013.790541. Epub 2013 May 7.

PMID:
23547839
12.

Expression of thymidine phosphorylase in lymph nodes involved with mycosis fungoides and sézary syndrome.

Nie X, Bhat R, Al-Saleem ED, Vonderheid EC, Hou JS.

Adv Hematol. 2011;2011:875135. doi: 10.1155/2011/875135. Epub 2011 Nov 14.

13.

Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome.

Hristov AC, Vonderheid EC, Borowitz MJ.

Am J Clin Pathol. 2011 Dec;136(6):944-53. doi: 10.1309/AJCP09OTJOYAVZZK.

PMID:
22095381
14.

High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides.

Kadin ME, Pavlov IY, Delgado JC, Vonderheid EC.

J Invest Dermatol. 2012 Mar;132(3 Pt 1):703-10. doi: 10.1038/jid.2011.351. Epub 2011 Nov 10.

15.

Lymphomatoid papulosis followed by pityriasis lichenoides: a common pathogenesis?

Vonderheid EC, Kadin ME, Gocke CD.

Am J Dermatopathol. 2011 Dec;33(8):835-40. doi: 10.1097/DAD.0b013e3181f4d8c3.

PMID:
22042257
16.

Cutaneous and systemic plasmacytosis vs. cutaneous plasmacytic castleman disease: review and speculations about pathogenesis.

Haque M, Hou JS, Hisamichi K, Tamada K, Cusack CA, Abdelmalek M, Brown RE, Vonderheid EC.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):453-61. doi: 10.1016/j.clml.2011.07.004. Epub 2011 Sep 21. Review.

PMID:
21940235
17.

Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC; International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

J Clin Oncol. 2011 Jun 20;29(18):2598-607. doi: 10.1200/JCO.2010.32.0630. Epub 2011 May 16.

18.

Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL).

Wu J, Siddiqui J, Nihal M, Vonderheid EC, Wood GS.

Arch Biochem Biophys. 2011 Apr 15;508(2):185-91. doi: 10.1016/j.abb.2010.10.020. Epub 2010 Oct 29.

19.

A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.

Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B.

J Am Acad Dermatol. 2010 Dec;63(6):984-90. doi: 10.1016/j.jaad.2010.02.039.

PMID:
20889234
20.

Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.

Kadin ME, Vonderheid EC.

Nat Rev Clin Oncol. 2010 Aug;7(8):430-2. doi: 10.1038/nrclinonc.2010.105. No abstract available.

PMID:
20668480
21.

Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome.

McGirt LY, Thoburn C, Hess A, Vonderheid EC.

Photodermatol Photoimmunol Photomed. 2010 Aug;26(4):182-91. doi: 10.1111/j.1600-0781.2010.00514.x.

22.

Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.

Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-Rodriguez C, Geskin LJ.

Clin Lymphoma Myeloma. 2009 Dec;9(6):412-6. doi: 10.3816/CLM.2009.n.082.

PMID:
19951879
23.

Toll-like receptor 2, 4, 7 and 9 expression in primary cutaneous CD30+ T-cell lymphoma.

Knol AC, Ehst BD, Dompmartin A, Quéreux G, Nguyen JM, Comoz F, Renaut JJ, Khammari A, Vonderheid EC, Dréno B.

Br J Dermatol. 2009 Dec;161(6):1414-6. doi: 10.1111/j.1365-2133.2009.09470.x. Epub 2009 Sep 28. No abstract available.

PMID:
19785598
24.

Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma.

Bisaccia E, Vonderheid EC, Geskin L.

Br J Dermatol. 2009 Jul;161(1):167-9. doi: 10.1111/j.1365-2133.2009.09081.x. Epub 2009 Mar 9.

PMID:
19298276
25.

Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.

Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS.

J Invest Dermatol. 2009 May;129(5):1165-73. doi: 10.1038/jid.2008.309. Epub 2008 Oct 16.

26.

Primary cutaneous CD30+ anaplastic large cell lymphoma responds to imiquimod cream.

Ehst BD, Dréno B, Vonderheid EC.

Eur J Dermatol. 2008 Jul-Aug;18(4):467-8. doi: 10.1684/ejd.2008.0450. Epub 2008 Jun 23. No abstract available.

PMID:
18573730
27.

Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.

Capriotti E, Vonderheid EC, Thoburn CJ, Wasik MA, Bahler DW, Hess AD.

Leuk Lymphoma. 2008 Jun;49(6):1190-201. doi: 10.1080/10428190802064917.

28.

Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.

Kazin R, Bujanauskas P, Vonderheid EC.

J Am Acad Dermatol. 2008 Feb;58(2 Suppl):S31-2. doi: 10.1016/j.jaad.2007.08.033. No abstract available.

PMID:
18191695
29.

CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry.

Bahler DW, Hartung L, Hill S, Bowen GM, Vonderheid EC.

Cytometry B Clin Cytom. 2008 May;74(3):156-62.

30.

Sézary syndrome coexisting with B-cell chronic lymphocytic leukemia: case report and review of the literature.

Karsai S, Hou JS, Telang G, Kantor GR, Nowell PC, Vonderheid EC.

Dermatology. 2008;216(1):68-75. Review.

PMID:
18032903
31.
32.

Differentiation of tumour-stage mycosis fungoides, psoriasis vulgaris and normal controls in a pilot study using serum proteomic analysis.

Cowen EW, Liu CW, Steinberg SM, Kang S, Vonderheid EC, Kwak HS, Booher S, Petricoin EF, Liotta LA, Whiteley G, Hwang ST.

Br J Dermatol. 2007 Nov;157(5):946-53. Epub 2007 Sep 13.

33.

Chemokine receptor expression by leukemic T cells of cutaneous T-cell lymphoma: clinical and histopathological correlations.

Capriotti E, Vonderheid EC, Thoburn CJ, Bright EC, Hess AD.

J Invest Dermatol. 2007 Dec;127(12):2882-92. Epub 2007 Jun 28.

34.

Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging.

Vonderheid EC, Pena J, Nowell P.

Leuk Lymphoma. 2006 Sep;47(9):1841-56.

PMID:
17064997
35.

Papular mycosis fungoides: a variant of mycosis fungoides or lymphomatoid papulosis?

Vonderheid EC, Kadin ME.

J Am Acad Dermatol. 2006 Jul;55(1):177-80. No abstract available.

PMID:
16781328
36.

Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis.

Mao X, Orchard G, Vonderheid EC, Nowell PC, Bagot M, Bensussan A, Russell-Jones R, Young BD, Whittaker SJ.

J Invest Dermatol. 2006 Jun;126(6):1388-95.

37.

On the diagnosis of erythrodermic cutaneous T-cell lymphoma.

Vonderheid EC.

J Cutan Pathol. 2006 Feb;33 Suppl 1:27-42. Review.

PMID:
16412210
38.

Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy.

Nebozhyn M, Loboda A, Kari L, Rook AH, Vonderheid EC, Lessin S, Berger C, Edelson R, Nichols C, Yousef M, Gudipati L, Shang M, Showe MK, Showe LC.

Blood. 2006 Apr 15;107(8):3189-96. Epub 2006 Jan 10.

39.

Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: search for recurrent chromosome abnormalities.

Batista DA, Vonderheid EC, Hawkins A, Morsberger L, Long P, Murphy KM, Griffin CA.

Genes Chromosomes Cancer. 2006 Apr;45(4):383-91.

PMID:
16382449
40.

Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing.

Nagasawa T, Zhang Q, Raghunath PN, Wong HY, El-Salem M, Szallasi A, Marzec M, Gimotty P, Rook AH, Vonderheid EC, Odum N, Wasik MA.

Leuk Res. 2006 Mar;30(3):303-12. Epub 2005 Sep 26.

PMID:
16185764
41.

T-cell clonality of peripheral blood lymphocytes in patients with lymphomatoid papulosis.

Schultz JC, Granados S, Vonderheid EC, Hwang ST.

J Am Acad Dermatol. 2005 Jul;53(1):152-5.

PMID:
15965440
42.

Do neoplastic stem cells underlie the pathogenesis of cutaneous lymphomas?

Vonderheid EC, Matsui W.

Arch Dermatol. 2005 May;141(5):641-2; author reply 642-3. No abstract available.

PMID:
15897396
43.

On the possible relationship between staphylococcal superantigens and increased Vbeta5.1 usage in cutaneous T-cell lymphoma.

Vonderheid EC, Bigler RD, Hou JS.

Br J Dermatol. 2005 Apr;152(4):825-6; author reply 827. No abstract available.

PMID:
15840139
44.

Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma.

Vonderheid EC, Boselli CM, Conroy M, Casaus L, Espinoza LC, Venkataramani P, Bigler RD, Hou JS.

J Invest Dermatol. 2005 Mar;124(3):651-61.

45.

BCL2 and JUNB abnormalities in primary cutaneous lymphomas.

Mao X, Orchard G, Lillington DM, Child FJ, Vonderheid EC, Nowell PC, Bagot M, Bensussan A, Russell-Jones R, Young BD, Whittaker SJ.

Br J Dermatol. 2004 Sep;151(3):546-56.

PMID:
15377339
46.

The Sézary syndrome: hematologic criteria.

Vonderheid EC, Bernengo MG.

Hematol Oncol Clin North Am. 2003 Dec;17(6):1367-89, viii. Review.

PMID:
14710890
47.

Treatment planning in cutaneous T-cell lymphoma.

Vonderheid EC.

Dermatol Ther. 2003;16(4):276-82. Review.

PMID:
14686969
48.

Improved sensitivity of T-cell clonality detection in mycosis fungoides by hand microdissection and heteroduplex analysis.

Dereure O, Levi E, Vonderheid EC, Kadin ME.

Arch Dermatol. 2003 Dec;139(12):1571-5.

PMID:
14676072
49.

Photopheresis: current and future perspectives.

Vonderheid EC.

J Cutan Med Surg. 2003 Jul-Aug;7(4 Suppl):1-2. No abstract available.

PMID:
12958699
50.

Secondary syphilis presenting as pseudolymphoma of the skin.

McComb ME, Telang GH, Vonderheid EC.

J Am Acad Dermatol. 2003 Aug;49(2 Suppl Case Reports):S174-6.

PMID:
12894114

Supplemental Content

Loading ...
Support Center